Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2015/428169 http://scihub22266oqcxt.onion/10.1155/2015/428169 C4436450!4436450!26075239     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biomed+Res+Int 2015 ; 2015 (ä): ä Nephropedia Template TP {{tp|p=26075239|t=2015. Adverse Events of Monoclonal Antibodies Used for Cancer Therapy |pdf=|usr=}}{{26075239}} gab.com Text Adverse Events of Monoclonal Antibodies Used for Cancer Therapy JO: Biomed Res Int http://www.kidney.de/pget.php?&tw=1&pmid=26075239 #FOAvip In 1997, the first monoclonal antibody (MoAb), the chimeric anti-CD20 molecule rituximab, was approved by the US Food and Drug administration for use in cancer patients. Since then, the panel of MoAbs that are approved by international regulatory agencies for the treatment of hematopoietic and solid malignancies has continued to expand, currently encompassing a stunning amount of 20 distinct molecules for 11 targets. We provide a brief scientific background on the use of MoAbs in cancer therapy, review all types of monoclonal antibodies-related adverse events (e.g., allergy, immune-related adverse events, cardiovascular adverse events, and pulmonary adverse events), and discuss the mechanism and treatment of adverse events. Twit Text FOAVip Adverse Events of Monoclonal Antibodies Used for Cancer Therapy ????Biomed Res Int http://www.kidney.de/pget.php?&tw=1&pmid=26075239 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26075239 #FOAvip English Wikipedia <ref>{{Cite pmid|26075239}}</ref> Adverse Events of Monoclonal Antibodies Used for Cancer Therapy #MMPMID26075239 Guan M; Zhou YP; Sun JL; Chen SC Biomed Res Int 2015[]; 2015 (ä): ä PMID26075239show ga In 1997, the first monoclonal antibody (MoAb), the chimeric anti-CD20 molecule rituximab, was approved by the US Food and Drug administration for use in cancer patients. Since then, the panel of MoAbs that are approved by international regulatory agencies for the treatment of hematopoietic and solid malignancies has continued to expand, currently encompassing a stunning amount of 20 distinct molecules for 11 targets. We provide a brief scientific background on the use of MoAbs in cancer therapy, review all types of monoclonal antibodies-related adverse events (e.g., allergy, immune-related adverse events, cardiovascular adverse events, and pulmonary adverse events), and discuss the mechanism and treatment of adverse events. äAdverse Events of Monoclonal Antibodies Used for Cancer Therapy (epmc).pdf DeepDyve Pubget Overpricing